The syngo Virtual Cockpit platform reportedly enables remote access and image acquisition for CT, MRI and positron emission tomography (PET), and facilitates clinician collaboration across multiple sites.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the syngo Virtual Cockpit, a multi-vendor remote scanning platform that may help facilitate improved access to advanced imaging for patients in remote locations.
The syngo Virtual Cockpit enables remote access for computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission CT (SPECT) imaging, according to Siemens Healthineers, the manufacturer of the software. The company said the remote platform also features live video and chat functionalities to foster collaboration between clinicians across multiple sites.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the syngo Virtual Cockpit, a multi-vendor remote scanning platform that may enable access to MRI, CT and positron emission tomography (PET) imaging for patients in remote locations.
In addition to possibly facilitating improved standardization for imaging of remote patients, Siemens Healthineers suggested the syngo Virtual Cockpit could be utilized in training staff at remote facilities.
“This FDA clearance means that our customers can use syngo Virtual Cockpit for their remote scanning operations with even more confidence that they are using a proven solution — one that prioritizes patient safety and convenience while also addressing operational and staffing challenges,” noted Peter Shen, head of digital and automation at Siemens Healthineers North America.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.